{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:51:50Z","timestamp":1785862310959,"version":"3.56.0"},"reference-count":37,"publisher":"The Endocrine Society","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG30526"],"award-info":[{"award-number":["IG30526"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union\u2014NextGenerationEU"},{"DOI":"10.13039\/501100003407","name":"Italian Ministry of University and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PNRR","award":["M4C2-I1.3"],"award-info":[{"award-number":["M4C2-I1.3"]}]},{"name":"PNRR","award":["PE_00000019"],"award-info":[{"award-number":["PE_00000019"]}]},{"name":"HEAL ITALIA"},{"DOI":"10.13039\/501100002862","name":"CUP","doi-asserted-by":"publisher","award":["I53C22001440006"],"award-info":[{"award-number":["I53C22001440006"]}],"id":[{"id":"10.13039\/501100002862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Erectile dysfunction (ED) is observed during treatment with the highly selective RET inhibitor selpercatinib. A pathogenic hypothesis is the impairment in the hypothalamic\u2013pituitary\u2013gonadal (HPG) axis. This study aims to analyze variations in the HPG axis in male patients with advanced medullary thyroid carcinoma (MTC) treated with selpercatinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 19 male patients were evaluated for FSH, LH, total testosterone (TT), and sex hormone binding globulin (SHBG). Free testosterone (FreeT) was estimated. In all patients (total group\u2014T-Group), the HPG axis was evaluated before and after 12 months of selpercatinib initiation. In 7\/19 (36.8%) cases (extended group\u2014Ex-Group), data collection was extended beyond 24 months from the start of treatment. Semen analysis was performed in 6 (31.6%) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 18\/19 (94.7%) patients experienced ED: 2 (11.1%) had ED before, while 16 (88.9%) developed ED after starting selpercatinib. The median time to ED onset was 1 month. During the first year of treatment, a significant increase in FSH (P = .03) (+61.9%) was observed in the T-Group. In the Ex-Group, a significant increase in FSH (+60.6%), LH (+20.5%) (P &amp;lt; .01), and SHBG (+27.7%) (P = .04), and a decrease in TT (\u221220%) (P = .01) and FreeT (\u221212.5%) (P &amp;lt; .01) were observed. Five patients had azoospermia, and one had severe oligospermia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ED shows high prevalence and early onset in males with MTC treated with selpercatinib. Impairment in the HPG axis and semen analysis can reflect damage to Sertoli and Leydig cells, leading to hypogonadism. Therefore, HPG axis evaluation and fertility counseling could be advisable mainly in childbearing males before starting selpercatinib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag296","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:57:05Z","timestamp":1784721425000},"source":"Crossref","is-referenced-by-count":0,"title":["Impairment in the hypothalamic\u2013pituitary\u2013gonadal axis in males with medullary thyroid carcinoma treated with selpercatinib"],"prefix":"10.1210","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4263-4717","authenticated-orcid":false,"given":"Antonio","family":"Matrone","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital , Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Gambale","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital , Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Prete","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital , Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5957-8902","authenticated-orcid":false,"given":"Cristina","family":"Romei","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital , Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Casalini","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital , Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Piaggi","sequence":"additional","affiliation":[{"name":"Department of Information Engineering, University of Pisa , Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Nencetti","sequence":"additional","affiliation":[{"name":"Laboratory of Chemistry and Endocrinology, University Hospital of Pisa , Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Sessa","sequence":"additional","affiliation":[{"name":"Laboratory of Chemistry and Endocrinology, University Hospital of Pisa , Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Canale","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital , Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5333-9257","authenticated-orcid":false,"given":"Rossella","family":"Elisei","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital , Pisa 56124 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"9","key":"2026080411511471200_dgag296-B1","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"2026080411511471200_dgag296-B2","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"2026080411511471200_dgag296-B3","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/oncolo\/oyae282","article-title":"Long-term safety of selpercatinib for rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time","volume":"29","author":"Raez","year":"2024","journal-title":"Oncologist"},{"issue":"12","key":"2026080411511471200_dgag296-B4","article-title":"Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers","volume":"4","author":"Nardo","year":"2023","journal-title":"Cell Rep Med"},{"issue":"6","key":"2026080411511471200_dgag296-B5","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1530\/EJE-22-0643","article-title":"Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib","volume":"187","author":"Prete","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2026080411511471200_dgag296-B6","doi-asserted-by":"crossref","first-page":"e3824","DOI":"10.1210\/clinem\/dgac337","article-title":"Selpercatinib treatment of RET-mutated thyroid cancers is associated with gastrointestinal adverse effects","volume":"107","author":"Tsang","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026080411511471200_dgag296-B7","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-24-0189","article-title":"Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib","volume":"13","author":"Gambale","year":"2024","journal-title":"Eur Thyroid J"},{"issue":"9","key":"2026080411511471200_dgag296-B8","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1089\/thy.2024.0129","article-title":"Erectile dysfunction in patients treated with selpercatinib for RET-altered thyroid cancer","volume":"34","author":"Matrone","year":"2024","journal-title":"Thyroid"},{"issue":"5457","key":"2026080411511471200_dgag296-B9","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1126\/science.287.5457.1489","article-title":"Regulation of cell fate decision of undifferentiated spermatogonia by GDNF","volume":"287","author":"Meng","year":"2000","journal-title":"Science"},{"issue":"3","key":"2026080411511471200_dgag296-B10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s13539-012-0065-7","article-title":"Hypogonadism in male cancer patients","volume":"3","author":"Burney","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"7","key":"2026080411511471200_dgag296-B11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1470-2045(10)70021-8","article-title":"Male hypogonadism associated with advanced cancer: a systematic review","volume":"11","author":"Vigano","year":"2010","journal-title":"Lancet Oncol"},{"key":"2026080411511471200_dgag296-B12","volume-title":"WHO Laboratory Manual for the Examination and Processing of Human Semen","year":"2021","edition":"6th ed"},{"issue":"2","key":"2026080411511471200_dgag296-B13","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"2026080411511471200_dgag296-B14","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1007\/s00432-022-03975-6","article-title":"Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS","volume":"148","author":"Riccetti","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2026080411511471200_dgag296-B15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/onco.13977","article-title":"Patient-reported outcomes with selpercatinib treatment among patients with RET-mutant medullary thyroid cancer in the phase I\/II LIBRETTO-001 trial","volume":"27","author":"Wirth","year":"2022","journal-title":"Oncologist"},{"issue":"706","key":"2026080411511471200_dgag296-B16","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.3399\/bjgp20X714197","article-title":"Prevalence of erectile dysfunction in male survivors of cancer: a systematic review and meta-analysis of cross-sectional studies","volume":"71","author":"Pizzol","year":"2021","journal-title":"Br J Gen Pract"},{"issue":"34","key":"2026080411511471200_dgag296-B17","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1200\/JCO.2010.30.3818","article-title":"Testosterone levels and quality of life in diverse male patients with cancers unrelated to androgens","volume":"28","author":"Fleishman","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"2026080411511471200_dgag296-B18","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1002\/cncr.27450","article-title":"Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer","volume":"118","author":"Weickhardt","year":"2012","journal-title":"Cancer"},{"issue":"15","key":"2026080411511471200_dgag296-B19","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1002\/cncr.35293","article-title":"Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK-positive advanced non-small cell lung cancer","volume":"130","author":"Vita","year":"2024","journal-title":"Cancer"},{"issue":"3","key":"2026080411511471200_dgag296-B20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/17843286.2018.1476115","article-title":"Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies","volume":"74","author":"Bastin","year":"2019","journal-title":"Acta Clin Belg"},{"issue":"13","key":"2026080411511471200_dgag296-B21","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/cncr.28089","article-title":"Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients","volume":"119","author":"Weickhardt","year":"2013","journal-title":"Cancer"},{"issue":"1","key":"2026080411511471200_dgag296-B22","doi-asserted-by":"crossref","first-page":"410","DOI":"10.21873\/invivo.13093","article-title":"Gonadal function in male patients with metastatic renal cell cancer treated with sunitinib","volume":"37","author":"Volta","year":"2023","journal-title":"In Vivo (Brooklyn)"},{"issue":"5","key":"2026080411511471200_dgag296-B23","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/COC.0b013e3182a46896","article-title":"Multiple endocrine disruption by the MET\/ALK inhibitor crizotinib in patients with non-small cell lung cancer","volume":"38","author":"Sargis","year":"2015","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"2026080411511471200_dgag296-B24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/1078155211424629","article-title":"Imatinib-associated bilateral gynecomastia and unilateral testicular hydrocele in male patient with metastatic gastrointestinal stromal tumor: a literature review","volume":"18","author":"Tanriverdi","year":"2012","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"2026080411511471200_dgag296-B25","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3346\/jkms.2005.20.3.512","article-title":"Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor","volume":"20","author":"Kim","year":"2005","journal-title":"J Korean Med Sci"},{"key":"2026080411511471200_dgag296-B26"},{"issue":"4","key":"2026080411511471200_dgag296-B27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041454","article-title":"Exposure to chemotherapy during childhood or adulthood and consequences on spermatogenesis and male fertility","volume":"21","author":"Delessard","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2026080411511471200_dgag296-B28","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/1097-0142(20010401)91:7<1297::AID-CNCR1132>3.0.CO;2-Z","article-title":"The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors","volume":"91","author":"Gerl","year":"2001","journal-title":"Cancer"},{"issue":"2","key":"2026080411511471200_dgag296-B29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/aja.aja_83_18","article-title":"Regulation of anti-Mullerian hormone (AMH) in males and the associations of serum AMH with the disorders of male fertility","volume":"21","author":"Xu","year":"2019","journal-title":"Asian J Androl"},{"issue":"10","key":"2026080411511471200_dgag296-B30","first-page":"3692","article-title":"Inhibin B in males with gonadotropin-releasing hormone (GnRH) deficiency: changes in serum concentration after shortterm physiologic GnRH replacement\u2013a clinical research center study","volume":"81","author":"Seminara","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2026080411511471200_dgag296-B31","article-title":"GDNF and the RET receptor in cancer: new insights and therapeutic potential","volume":"9","author":"Mulligan","year":"2018","journal-title":"Front Physiol"},{"issue":"2 Suppl 2","key":"2026080411511471200_dgag296-B32","first-page":"173","article-title":"Glial cell line-derived neurotrophic factor (GDNF) and its receptors GFRalpha-1 and GFRalpha-2 in the human testis","volume":"106","author":"Davidoff","year":"2001","journal-title":"Ital J Anat Embryol"},{"issue":"3","key":"2026080411511471200_dgag296-B33","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1530\/REP-18-0239","article-title":"Regulation of GDNF expression in Sertoli cells","volume":"157","author":"Parekh","year":"2019","journal-title":"Reproduction"},{"issue":"6","key":"2026080411511471200_dgag296-B34","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00496","article-title":"Selpercatinib-induced hypothyroidism through off-target inhibition of type 2 iodothyronine deiodinase","volume":"6","author":"Boucai","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"2026080411511471200_dgag296-B35","doi-asserted-by":"crossref","first-page":"591","DOI":"10.21037\/tau.2020.01.13","article-title":"Do testosterone supplements enhance response to phosphodiesterase 5 inhibitors in men with erectile dysfunction and hypogonadism: a systematic review and meta-analysis","volume":"9","author":"Zhu","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"5","key":"2026080411511471200_dgag296-B36","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1517\/14656566.2015.1011124","article-title":"Does testosterone supplementation increase PDE5-inhibitor responses in difficult-to-treat erectile dysfunction patients?","volume":"16","author":"Aversa","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"2026080411511471200_dgag296-B37","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1210\/jc.2010-2771","article-title":"Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer","volume":"96","author":"Brassard","year":"2011","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag296\/69857837\/dgag296.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag296\/69857837\/dgag296.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:51:25Z","timestamp":1785858685000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article\/doi\/10.1210\/clinem\/dgag296\/8740375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":37,"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag296","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"dgag296"}}